Closed, Automated Manufacturing of CD19-CAR T Cells Using Cocoon® Platform and Gibco™ CTS™ Rotea™ for Harvest
This technical application poster, originally showcased at CAR TCR 2023, shares data demonstrating one of OmniaBio’s closed, automated CAR T manufacturing platforms that can be tailored to accommodate specific client needs. This poster shows the integration of the CliniMACS® Plus System (Miltenyi Biotec) for T cell isolation, Cocoon® Platform (Lonza) for T cell activation, viral transduction, and expansion, and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System (Thermo Fisher Scientific) for thorough washing, volume reduction, and formulation, presenting a platform that can advance your CAR T cell therapy manufacturing path. The platform developed is a robust CAR T manufacturing process with benefits related to process closure and automation while also showing evidence of successful genetic modification.
While CAR T therapies have shown remarkable success in oncology and continue to be evaluated to address other devastating diseases, manufacturing remains a challenge. Selecting the optimal manufacturing platform often comes down to program specific requirements. Leveraging a development team with experience evaluating the performance of multiple CAR T manufacturing technology and approaches with the end in mind can help you select the right manufacturing platform upfront that will meet your manufacturing strategy goals streamlining your path to market.
Download this poster to learn how we can help streamline your CAR T program journey to market.
About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
